Atopic Dermatitis

In the CHECK study, a cross-sectional survey of over 10,000 participants, the prevalence of chronic hand eczema (CHE) in the US was highlighted.

In this segment of her Fall Clinical interview, Shahriari highlights a session IL-13 inhibition and management of atopic dermatitis.

These recent findings on roflumilast cream (Zoryve) highlight the topical agent’s efficacy and impacts on quality of life in younger patients with atopic dermatitis.

Lilly's lebrikizumab-lbkz treatment, used once every 8 weeks, resulted in durable disease control in moderate-to-severe atopic dermatitis.

Experts discuss how innovative treatments are revolutionizing atopic dermatitis care for children.

This interview segment with Irvine highlighted his team’s data presented at EADV regarding children 6-11 years with atopic dermatitis on dupilumab.

In this interview, improvements observed in children 6-11 years with severe atopic dermatitis following dupilumab use were spotlighted.

In this segment of her EADV interview, Markowitz highlights 3-D imaging data from the DISCOVER study on dupilumab (Dupixent) and atopic dermatitis in skin of color.

An audio recap of the top 5 stories in healthcare news from the week of 10/5-10/11.

This EADV interview features a discussion of data from the DISCOVER study on the effects of dupilumab (Dupixent) on atopic dermatitis in skin of color.

In this interview, additional information on roflumilast (Zoryve) cream 0.05% for patients aged 2-5 years with atopic dermatitis was highlighted.

A pair of leading subject matter experts discuss the current landscape of atopic dermatitis, including unmet needs, and the role of IL-13 inhibition in the management.

This interview follows the FDA’s recent approval of Arcutis's roflumilast (Zoryve) cream 0.05% for patients aged 2-5 years with atopic dermatitis.

The approval is supported by data from the INTEGUMENT-PED phase 3 trial, the INTEGUMENT-OLE long-term extension study, and a phase 1 pharmacokinetic study.

In this set of interviews, 6 leaders in the field of dermatology highlight their experiences at the 2025 EADV Congress.

A pair of leading subject matter experts discuss the current landscape of atopic dermatitis, including unmet needs, and the role of IL-13 inhibition in the management.

A compilation of 14 trials presented as late-breaking data at EADV 2025 Congress.

These data from the ECZTRA 3 and ECZTEND trials highlight tralokinumab’s impact on patients with atopic dermatitis long-term.

Weidinger discusses results from a pair of late-breaking presentations on temtokibart in atopic dermatitis from EADV 2025.

In this interview at EADV, Hong speaks about his team’s findings on IL-22RA1 antagonism with temtokibart and its impact on atopic dermatitis.

This interview segment with Bunick at EADV highlights some of the significance of these recent findings on cardiovascular risk and upadacitinib use over 6 years.

These late-breaking data at EADV highlight the impacts of ATI-2138, an oral small-molecule ITK/JAK3 inhibitor, on atopic dermatitis.

EADV 2025 findings show patients with atopic eczema face greater risks of depression, anxiety, sleep disorders, and stigmatization.

In this EADV interview, Bunick touches on his team’s findings related to risk of VTE, MACE, and malignancy in patients with atopic dermatitis treated with upadacitinib for 6 years.

In this analysis, the long-term cardiovascular safety of upadacitinib treatment for atopic dermatitis was highlighted.